Working… Menu

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03745716
Recruitment Status : Active, not recruiting
First Posted : November 19, 2018
Last Update Posted : July 29, 2021
Information provided by (Responsible Party):
Aprea Therapeutics

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : November 27, 2020
Estimated Study Completion Date : December 2021